Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACR Roundup: JAK Safety Shown Across Multiple Trials

Executive Summary

Low cardiovascular risk was shown in trials presented at the ACR/ARHP annual meeting for Pfizer's, Lilly's and AbbVie's JAK inhibitors in rheumatoid arthritis; AbbVie's Phase II risankizumab results in PsA, biosimilar doubts and more from ACR.

Advertisement

Related Content

ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Is Triple Phase III Triumph for AbbVie's Risankizumab In Psoriasis Good Enough?
Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path
AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms
Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All
Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
Safety Issues Not Dampening AbbVie Optimism For Humira Successors
Boehringer Ingelheim Limbering Up With Humira Biosimilar
Boehringer Hopes To Tap AbbVie's ''Humira Magic'' In Immunology Pact

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel